Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review.

Arend R, Westin SN, Coleman RL.

Int J Gynecol Cancer. 2020 Feb 19. pii: ijgc-2019-001041. doi: 10.1136/ijgc-2019-001041. [Epub ahead of print] Review.

PMID:
32079709
2.

Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study.

Yeung AR, Pugh SL, Klopp AH, Gil KM, Wenzel L, Westin SN, Gaffney DK, Small W Jr, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Deshmukh S, Bruner DW, Kachnic LA.

J Clin Oncol. 2020 Feb 19:JCO1902381. doi: 10.1200/JCO.19.02381. [Epub ahead of print]

PMID:
32073955
3.

Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma.

Berg HF, Ju Z, Myrvold M, Fasmer KE, Halle MK, Hoivik EA, Westin SN, Trovik J, Haldorsen IS, Mills GB, Krakstad C, Werner HMJ.

Br J Cancer. 2020 Feb 10. doi: 10.1038/s41416-020-0745-6. [Epub ahead of print]

PMID:
32037399
4.

Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Markham MJ, Wachter K, Agarwal N, Bertagnolli MM, Chang SM, Dale W, Diefenbach CSM, Rodriguez-Galindo C, George DJ, Gilligan TD, Harvey RD, Johnson ML, Kimple RJ, Knoll MA, LoConte N, Maki RG, Meisel JL, Meyerhardt JA, Pennell NA, Rocque GB, Sabel MS, Schilsky RL, Schneider BJ, Tap WD, Uzzo RG, Westin SN.

J Clin Oncol. 2020 Apr 1;38(10):1081. doi: 10.1200/JCO.19.03141. Epub 2020 Feb 4.

PMID:
32013670
5.

Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers.

Lakomy DS, Urbauer DL, Westin SN, Lin LL.

Clin Transl Radiat Oncol. 2019 Dec 28;21:56-61. doi: 10.1016/j.ctro.2019.12.005. eCollection 2020 Mar.

6.

Implementation of a sentinel lymph node mapping algorithm for endometrial cancer: surgical outcomes and hospital charges.

Stewart KI, Eska JS, Harrison RF, Suidan R, Abraham A, Chisholm GB, Meyer LA, Westin SN, Fleming ND, Frumovitz M, Aloia TA, Soliman PT.

Int J Gynecol Cancer. 2020 Mar;30(3):352-357. doi: 10.1136/ijgc-2019-000941. Epub 2020 Jan 6.

PMID:
31911539
7.

Body mass index and attitudes towards health behaviors among women with endometrial cancer before and after treatment.

Harrison R, Zhao H, Sun CC, Fu S, Armbruster SD, Westin SN, Rauh-Hain JA, Lu KH, Giordano SH, Meyer LA.

Int J Gynecol Cancer. 2020 Feb;30(2):187-192. doi: 10.1136/ijgc-2019-000999. Epub 2019 Dec 15.

PMID:
31843871
8.

Using Reverse Phase Protein Array (RPPA) to Identify and Target Adaptive Resistance.

Labrie M, Fang Y, Kendsersky ND, Li J, Liang H, Westin SN, Mitri Z, Mills GB.

Adv Exp Med Biol. 2019;1188:251-266. doi: 10.1007/978-981-32-9755-5_14. Review.

PMID:
31820393
9.

Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors.

Zibetti Dal Molin G, Westin SN, Msaouel P, Gomes LM, Dickens A, Coleman RL.

Int J Gynecol Cancer. 2020 Jan;30(1):89-93. doi: 10.1136/ijgc-2019-000714. Epub 2019 Dec 1.

PMID:
31792084
10.

Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma.

Lara OD, Krishnan S, Wang Z, Corvigno S, Zhong Y, Lyons Y, Dood R, Hu W, Qi L, Liu J, Coleman RL, Westin SN, Fleming ND, Cristini V, Rao A, Burks J, Sood AK.

Sci Rep. 2019 Nov 26;9(1):17589. doi: 10.1038/s41598-019-53872-1.

11.

Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.

Myers AP, Konstantinopoulos PA, Barry WT, Luo W, Broaddus RR, Makker V, Drapkin R, Liu J, Doyle A, Horowitz NS, Meric-Bernstam F, Birrer M, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN.

Int J Cancer. 2019 Nov 12. doi: 10.1002/ijc.32783. [Epub ahead of print]

PMID:
31714586
12.

Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study.

Gallagher JR, Heap KJ, Carroll S, Travers K, Harrow B, Westin SN.

Future Oncol. 2019 Dec;15(36):4197-4206. doi: 10.2217/fon-2019-0471. Epub 2019 Nov 11.

13.

Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study.

Soliman PT, Westin SN, Iglesias DA, Fellman BM, Yuan Y, Zhang Q, Yates MS, Broaddus RR, Slomovitz BM, Lu KH, Coleman RL.

Clin Cancer Res. 2020 Feb 1;26(3):581-587. doi: 10.1158/1078-0432.CCR-19-0471. Epub 2019 Oct 18.

PMID:
31628143
14.

Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.

Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C.

Gynecol Oncol. 2019 Dec;155(3):420-428. doi: 10.1016/j.ygyno.2019.09.024. Epub 2019 Oct 15.

PMID:
31623857
15.

Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression.

Ramondetta LM, Hu W, Thaker PH, Urbauer DL, Chisholm GB, Westin SN, Sun Y, Ramirez PT, Fleming N, Sahai SK, Nick AM, Arevalo JMG, Dizon T, Coleman RL, Cole SW, Sood AK.

Gynecol Oncol. 2019 Sep;154(3):524-530. doi: 10.1016/j.ygyno.2019.07.004. Epub 2019 Jul 25.

PMID:
31353053
16.

Rapidly Changing Landscape of Fallopian Tube Carcinoma.

Kurnit KC, Lu KH, Westin SN.

J Oncol Pract. 2019 Jul;15(7):383-384. doi: 10.1200/JOP.19.00248. Epub 2019 Jul 8. No abstract available.

PMID:
31283416
17.

Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high-risk endometrial cancer: A prospective study.

Stewart KI, Chasen B, Erwin W, Fleming N, Westin SN, Dioun S, Frumovitz M, Ramirez PT, Lu KH, Wong F, Aloia TA, Soliman PT.

Cancer. 2019 Oct 1;125(19):3347-3353. doi: 10.1002/cncr.32329. Epub 2019 Jun 21.

PMID:
31225906
18.

Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience.

Armbruster SD, Previs R, Soliman PT, Westin SN, Fellman B, Jhingran A, Fleming ND.

Gynecol Oncol. 2019 Aug;154(2):328-332. doi: 10.1016/j.ygyno.2019.06.001. Epub 2019 Jun 18.

PMID:
31221496
19.

Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options.

Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN.

Oncotarget. 2019 May 28;10(37):3533-3546. doi: 10.18632/oncotarget.26947. eCollection 2019 May 28.

20.

Understanding the Role of Advanced Practice Providers in Oncology in the United States.

Bruinooge SS, Pickard TA, Vogel W, Hanley A, Schenkel C, Garrett-Mayer E, Tetzlaff E, Rosenzweig M, Hylton H, Westin SN, Smith N, Lynch C, Kosty MP, Williams SF.

J Adv Pract Oncol. 2018 Sep-Oct;9(6):585-598. Epub 2018 Sep 1. Review.

21.

Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.

Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, Ju Z, Vellano CP, Lu Y, Li Y, Jeong KJ, Ding Z, Liang J, Wang SW, Dai H, Lee S, Sahni N, Mercado-Uribe I, Kim TB, Chen K, Lin SY, Peng G, Westin SN, Liu J, O'Connor MJ, Yap TA, Mills GB.

Cancer Cell. 2019 Jun 10;35(6):851-867.e7. doi: 10.1016/j.ccell.2019.05.001.

PMID:
31185210
22.

National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia.

Harrison RF, He W, Fu S, Zhao H, Sun CC, Suidan RS, Woodard TL, Rauh-Hain JA, Westin SN, Giordano SH, Meyer LA.

Am J Obstet Gynecol. 2019 Nov;221(5):474.e1-474.e11. doi: 10.1016/j.ajog.2019.05.029. Epub 2019 May 22.

PMID:
31128110
23.

Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies.

Hinchcliff E, Westin SN, Dal Molin G, LaFargue CJ, Coleman RL.

Int J Gynecol Cancer. 2019 May 22. pii: ijgc-2019-000499. doi: 10.1136/ijgc-2019-000499. [Epub ahead of print]

PMID:
31118216
24.

Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer.

Chapman BV, Swanick CW, Ning MS, Allen PK, Soliman PT, Westin SN, Pardeshi V, Broaddus RR, Lu KH, Jhingran A, Eifel PJ, Klopp AH.

Gynecol Oncol. 2019 Jul;154(1):22-28. doi: 10.1016/j.ygyno.2019.05.002. Epub 2019 May 17.

PMID:
31109659
25.

Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapy.

Gil KM, Pugh SL, Klopp AH, Yeung AR, Wenzel L, Westin SN, Gaffney DK, Small W Jr, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Deshmukh S, Kachnic LA, Bruner DW.

Gynecol Oncol. 2019 Jul;154(1):183-188. doi: 10.1016/j.ygyno.2019.04.682. Epub 2019 May 16.

PMID:
31104905
26.

Intraoperative Air Leak Test to Prevent Bile Leak After Right Posterior Sectionectomy with En Bloc Diaphragm Resection for Metastatic Teratoma.

Vreeland TJ, Beaudry Simoneau E, Dewhurst WL, Newhook TE, Westin SN, Mehran RJ, Chun YS, Aloia TA, Vauthey JN, Tzeng CD.

Ann Surg Oncol. 2019 Aug;26(8):2579. doi: 10.1245/s10434-019-07410-y. Epub 2019 May 7.

PMID:
31065963
27.

Microsatellite instability in endometrial cancer: New purpose for an old test.

Kurnit KC, Westin SN, Coleman RL.

Cancer. 2019 Jul 1;125(13):2154-2163. doi: 10.1002/cncr.32058. Epub 2019 Mar 26. No abstract available.

PMID:
30913308
28.

Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.

Buechel M, Herzog TJ, Westin SN, Coleman RL, Monk BJ, Moore KN.

Ann Oncol. 2019 May 1;30(5):721-732. doi: 10.1093/annonc/mdz104.

29.

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.

Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA.

Lancet Oncol. 2019 Apr;20(4):570-580. doi: 10.1016/S1470-2045(18)30905-7. Epub 2019 Mar 14.

PMID:
30880072
30.

Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Pal SK, Miller MJ, Agarwal N, Chang SM, Chavez-MacGregor M, Cohen E, Cole S, Dale W, Magid Diefenbach CS, Disis ML, Dreicer R, Graham DL, Henry NL, Jones J, Keedy V, Klepin HD, Markham MJ, Mittendorf EA, Rodriguez-Galindo C, Sabel MS, Schilsky RL, Sznol M, Tap WD, Westin SN, Johnson BE.

J Clin Oncol. 2019 Apr 1;37(10):834-849. doi: 10.1200/JCO.18.02037. Epub 2019 Jan 31. No abstract available.

PMID:
30702028
31.

Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.

Kurnit KC, Coleman RL, Westin SN.

Curr Treat Options Oncol. 2018 Nov 15;19(12):1. doi: 10.1007/s11864-018-0572-7. Review.

PMID:
30535808
32.

Understanding the role of advanced practice providers in oncology in the United States.

Bruinooge SS, Pickard TA, Vogel W, Hanley A, Schenkel C, Garrett-Mayer E, Tetzlaff E, Rosenzweig M, Hylton H, Westin SN, Smith N, Lynch C, Kosty MP, Williams SF.

JAAPA. 2018 Dec;31(12):1-12. doi: 10.1097/01.JAA.0000549592.10756.4a. Review.

PMID:
30489397
33.

Prognostic factors impacting survival in early stage uterine carcinosarcoma.

Kurnit KC, Previs RA, Soliman PT, Westin SN, Klopp AH, Fellman BM, Lu KH, Ramondetta LM, Fleming ND.

Gynecol Oncol. 2019 Jan;152(1):31-37. doi: 10.1016/j.ygyno.2018.10.034. Epub 2018 Nov 8.

34.

Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer.

Hansen JM, Sood AK, Coleman RL, Westin SN, Soliman PT, Ramirez PT, Fellman BM, Schmeler KM, Fleming ND.

Gynecol Oncol. 2018 Dec;151(3):428-432. doi: 10.1016/j.ygyno.2018.10.017. Epub 2018 Oct 23.

35.

Understanding the Role of Advanced Practice Providers in Oncology in the United States.

Bruinooge S, Pickard TA, Vogel W, Hanley A, Schenkel C, Garrett-Mayer E, Tetzlaff E, Rosenzweig M, Hylton H, Westin SN, Smith N, Lynch C, Kosty MP, Williams SF.

Oncol Nurs Forum. 2018 Nov 1;45(6):786-800. doi: 10.1188/18.ONF.786-800.

PMID:
30339144
36.

Moving From Mutation to Actionability.

Colombo I, Kurnit KC, Westin SN, Oza AM.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:495-503. doi: 10.1200/EDBK_199665. Review.

37.

A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.

Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, Lu KH, Westin SN.

Gynecol Oncol. 2018 Nov;151(2):374-380. doi: 10.1016/j.ygyno.2018.08.037. Epub 2018 Sep 10. Review.

38.

Race and nodal disease status are prognostic factors in patients with stage IVB cervical cancer.

Nishio S, Matsuo K, Yonemoto K, Shimokawa M, Hosaka M, Kodama M, Miyake TM, Ushijima K, Kamura T, Westin SN, Soliman PT, Coleman RL.

Oncotarget. 2018 Aug 17;9(64):32321-32330. doi: 10.18632/oncotarget.25962. eCollection 2018 Aug 17.

39.

Understanding the Role of Advanced Practice Providers in Oncology in the United States.

Bruinooge SS, Pickard TA, Vogel W, Hanley A, Schenkel C, Garrett-Mayer E, Tetzlaff E, Rosenzweig M, Hylton H, Westin SN, Smith N, Lynch C, Kosty MP, Williams SF.

J Oncol Pract. 2018 Sep;14(9):e518-e532. doi: 10.1200/JOP.18.00181. Epub 2018 Aug 22. Erratum in: J Oncol Pract. 2019 Jan;15(1):60.

PMID:
30133346
40.

Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.

Dal Molin GZ, Westin SN, Coleman RL.

Future Oncol. 2018 Dec;14(30):3101-3110. doi: 10.2217/fon-2018-0215. Epub 2018 Aug 14. Review.

41.

Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer.

Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, Fellman B, Meyer LA, Schmeler KM, Lu KH, Sood AK.

Obstet Gynecol. 2018 Sep;132(3):545-554. doi: 10.1097/AOG.0000000000002796.

42.

When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System.

Dood RL, Fleming ND, Coleman RL, Westin SN, Lara OD, LaFargue CJ, Liu J, Sood AK.

Int J Gynecol Cancer. 2018 Oct;28(8):1485-1490. doi: 10.1097/IGC.0000000000001329.

43.

The influence of surgeon volume on outcomes after pelvic exenteration for a gynecologic cancer.

Jalloul RJ, Nick AM, Munsell MF, Westin SN, Ramirez PT, Frumovitz M, Soliman PT.

J Gynecol Oncol. 2018 Sep;29(5):e68. doi: 10.3802/jgo.2018.29.e68. Epub 2018 May 4.

44.

Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203.

Klopp AH, Yeung AR, Deshmukh S, Gil KM, Wenzel L, Westin SN, Gifford K, Gaffney DK, Small W Jr, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Pugh SL, Kachnic LA, Bruner DW.

J Clin Oncol. 2018 Aug 20;36(24):2538-2544. doi: 10.1200/JCO.2017.77.4273. Epub 2018 Jul 10. Erratum in: J Clin Oncol. 2019 Mar 20;37(9):761. Erratum in: J Clin Oncol. 2020 Apr 1;38(10):1118.

45.

Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis.

Suidan RS, Sun CC, Cantor SB, Mariani A, Soliman PT, Westin SN, Lu KH, Giordano SH, Meyer LA.

Obstet Gynecol. 2018 Jul;132(1):52-58. doi: 10.1097/AOG.0000000000002677.

46.

Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration.

Armbruster SD, Sun CC, Westin SN, Bodurka DC, Ramondetta L, Meyer LA, Soliman PT.

Gynecol Oncol. 2018 Jun;149(3):484-490. doi: 10.1016/j.ygyno.2018.03.054. Epub 2018 Apr 2.

47.

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Heymach J, Krilov L, Alberg A, Baxter N, Chang SM, Corcoran RB, Dale W, DeMichele A, Magid Diefenbach CS, Dreicer R, Epstein AS, Gillison ML, Graham DL, Jones J, Ko AH, Lopez AM, Maki RG, Rodriguez-Galindo C, Schilsky RL, Sznol M, Westin SN, Burstein H.

J Clin Oncol. 2018 Apr 1;36(10):1020-1044. doi: 10.1200/JCO.2017.77.0446. Epub 2018 Jan 30.

PMID:
29380678
48.

Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients.

Mauland KK, Ju Z, Tangen IL, Berg A, Kalland KH, Øyan AM, Bjørge L, Westin SN, Krakstad C, Trovik J, Mills GB, Hoivik EA, Johanna Werner HM.

Oncotarget. 2017 Oct 31;8(63):106989-107001. doi: 10.18632/oncotarget.22203. eCollection 2017 Dec 5.

49.

Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device.

Pal N, Broaddus RR, Urbauer DL, Balakrishnan N, Milbourne A, Schmeler KM, Meyer LA, Soliman PT, Lu KH, Ramirez PT, Ramondetta L, Bodurka DC, Westin SN.

Obstet Gynecol. 2018 Jan;131(1):109-116. doi: 10.1097/AOG.0000000000002390.

50.

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.

Banerji U, Dean EJ, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM.

Clin Cancer Res. 2018 May 1;24(9):2050-2059. doi: 10.1158/1078-0432.CCR-17-2260. Epub 2017 Oct 24.

Supplemental Content

Loading ...
Support Center